Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

# Appointment of leading Chief Financial Officer further strengthens leadership team

**Highlights:**

- **Mr Dan O'Connell appointed as Chief Financial Officer (CFO) bringing over 20 years of expertise in accounting and finance, tax, cross-border M&A, procurement, shared services, government and industry relations**
- **Mr. O'Connell was previously CFO of Newcrest Mining Limited (an ASX 20 company) until it was acquired by the world's largest gold mining company, Newmont Corporation**
- **He has also held a number of positions of increasing seniority at Newcrest, Kingsgate Consolidated Limited, BHP Billiton and Ernst & Young**
- **Mr. O'Connell will focus on bringing the Company's finance functionality in-house, delivering operational efficiencies, supporting capital planning and investment strategy, and helping advance the commercialisation of NUZ-001**
- **Appointment complements three recent high-calibre additions to NUZ's management team which include focus on regulatory affairs, preclinical and clinical development, and commercialisation**

**22 April 2025 – Melbourne, Australia:** Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Mr Dan O'Connell as Chief Financial Officer. Mr. O'Connell is a prominent senior executive with over 20 years of experience in multinational companies. He possesses extensive knowledge in accounting and finance, cross-border M&A, procurement, shared services, investor relations and communications, government and industry relations, and tax.

Most recently, Mr. O'Connell was Chief Financial Officer of Kingsgate Consolidated Limited (ASX: KCN) from July 2024 to February 2025. Just prior to this, he was interim CFO of Newcrest Mining Limited (an ASX 20 company) from December 2022 until it was acquired by the world's largest gold mining company, Newmont Corporation (ASX: NEM) in November 2023.

Mr. O'Connell also held multiple positions of increasing seniority since commencement at Newcrest Mining Limited, including Head of Tax (May 2012 – September 2017), GM – Accounting & Finance (August 2016 – February 2017), Commercial Manager – Cadia (October 2017 – September 2020) and Treasurer, which included a transitional role as Manager – Treasury Markets (September 2020 – December 2022).

Prior to his time with Newcrest, Mr O'Connell held roles with BHP Billiton and Ernst & Young. He holds a Bachelor of Commerce with Honours and a Bachelor of Arts from Monash University, a Master of Tax from the University of Melbourne and is a Certified Practicing Accountant (CPA).

This appointment will support Neurizon's transition to in-house financial operations, which is anticipated to yield cost savings and will equip the Company with significant additional expertise as it progresses its strategy to advance the commercialisation of its lead drug candidate, NUZ-001, encompassing regulatory approvals, neurodegenerative disease pipeline expansion, and prospective market access opportunities.

Mr. O'Connell will also play a key role in overseeing the Company's capital management strategy, investor relations, and financial planning activities, with a focus on aligning Neurizon's financial operations to long-term value creation. His experience in cross-border M&A and treasury operations will support the Company's capital needs as it prepares for commercial readiness, strategic partnerships, and future growth initiatives.

Mr. O'Connell's role as Chief Financial Officer complements and enhances the Company's recent appointments, which include Ms. Kathryn Williams as Chief Regulatory Officer (CRO), Dr. Jeffrey M. Brown as Chief Scientific Advisor (CSA), and Dr. Chris Freitag as Chief Medical Advisor (CMA), providing broader expertise in regulatory affairs, preclinical and clinical development, and commercialisation (refer ASX announcement: 17 April 2025).

**Chief Financial Officer, Mr. Dan O'Connell said:** "I am thrilled to be joining Neurizon during this crucial phase of its growth trajectory. I look forward to working with the Board, Michael and the broader management team as we transition into late-stage development and prepare for rapid commercialisation. In the near term, my focus will be to utilise my commercial and finance experience to optimise the Company's in-house finance functions, ensuring the best commercial outcomes for shareholders."

**Managing Director and Chief Executive Officer Dr. Michael Thurn said**: "We are very pleased to have attracted someone of Dan's calibre as CFO. Over a longstanding career, he has developed extensive R&D, commercial and business development experience, as well as cross-border M&A, government and industry relations expertise. We look forward to leveraging his skillset to capitalise on the Company's next phase of growth.'

"Dan's appointment, alongside the recent additions to our senior leadership team, reflects our continued focus on building a high-performing executive team with the capabilities needed to drive clinical success, commercial execution, and long-term value for our shareholders. It also strengthens the Board's confidence in the Company's ability to commercialise NUZ-001 as a treatment option, while delivering improved outcomes for patients with neurodegenerative diseases."

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

**Dr. Michael Thurn**
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

**Lidija Damjanovic**
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

**Released through:** Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

## About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

## Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited.